

TENDER NO. BMSIC/DRUGS/24-03						
Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids						
Company Name : -Pushkar Pharma. Total Number of Pages Submitted in bid documents: -1-100						
Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein.	Yes	16	Yes	—
2	3.(b)	EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount 1 Upto 5 drugs Rs1,00,000/- (One Lakh only) 2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only) 3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only) 4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only) 5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	Yes	23-26	Yes	As per Bid document clause 3(b) BG Submitted for EMD must be Schedule/Nationalized Bank Payable at Patna But firm has not submitted the same.
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	12-15	Yes	—
4	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	83	Yes	—
5	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	07-08	Yes	—
6	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	Yes	35-44	Yes	—
7	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	Yes	27-29	Yes	—
8	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	30	Yes	—
9	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	Yes	4-6	Yes	—

Anhang
24/07/24


104

TENDER NO. BMSIC/DRUGS/24-03

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Pushkar Pharma. Total Number of Pages Submitted in bid documents:- 100

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	83	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	7 & 8	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the quoted product.	Yes	45-62	No	Pack size of quoted product NIT sl. No. 42 is not as per NIT.
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	45-62	No	
5		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945.	Yes	63-80	No	Last year MSC of quoted product NIT sl. No. 37 & 42 not submitted.
6		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	

Anita
12/7/24Nitya Bala
12/07/2024
 16/7/24
 16/07/24

7		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	Yes	87-89	No	Challan for Pollution consent renewal is not submitted.
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	45-62	No	Pack size of quoted product NIT sl. No. 42 is not as per NIT.
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	NA	NA	NA	
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	17-21	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandisthat the GMP certificate should remain valid till the date of submission of tender.	Yes	9	Yes	
14	3.(k)	Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.	Yes	10	Yes	

Anur
12/7/24

aluty Balg
12/07/2024

NM
16/07/24
16/7/24

15	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed /Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL asper Annexure-II.	Yes	1	Yes	
16	3. (o)	List of items quoted in prescribed format as per Annexure-III duly signed.	Yes	2 & 3	Yes	
17	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV.	Yes	34	Yes	
18	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	81-82	Yes	
19	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	7 & 8	Yes	
20	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	NA	NA	NA	
21	2(d) Explanation	The price quoted by the bidders must not exceed the ceiling price as fixed by NPPA (National Pharmaceutical Pricing Authority) as per the provision of "Drugs Price Control Order" (wherever applicable) and the quoted rate should be at least 20% less than its MRP. In extraordinary cases the Managing Director, BMSICL has discretion to take decision. Explanation- In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in Annexure-VIII.	Yes	84	Yes	

Anita
12/7/24

Ality Bala
12/07/2024

16/7/24
18/7/24

TENDER NO. BMSIC/DRUGS/24-03

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Pushkar Pharma. Total Number of Pages Submitted in bid documents:- 100

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	3	Amikacin	Amikacin Sulphate Injection IP 500 mg/2ml	500 mg	Each 2 ml contains: Amikacin Sulphate IP Eq. to Amikacin 500 mg	2 ml Vial	2 ml, 5 ml, 10 ml, 15 ml, 20 ml, 30 ml	Injection	Injection	09.01.2009	08.01.2029	Generic	Submitted (page no. 76)
2	10	Cefotaxime	Cefotaxime Injection IP 125 mg	125 mg	Each vial contains: Sterile Cefotaxime Sodium Eq. to anhydrous (Cefotaxime IP 125)	Vial	Vial	Injection	Injection	13.09.2016	08.01.2029	Generic	Submitted (page no. 71)
3	11	Ceftriaxone	Ceftriaxone Injection IP 250 mg	250mg	Each vial contains: Ceftriaxone Sodium (Sterile) Eq. to Anhydrous Ceftriaxone IP 250 mg	Vial	Vial	Powder for Injection	Powder for Injection	09.01.2009	08.01.2029	Generic	Submitted (page no. 64)
4	12	Ceftriaxone	Ceftriaxone Injection IP 1 gm	1g	Each vial contains: Ceftriaxone Sodium (Sterile) Eq. to Anhydrous Ceftriaxone IP 1000 mg	Vial	Vial	Powder for Injection	Powder for Injection	09.01.2009	08.01.2029	Generic	Submitted (page no. 68)
5	19	Etophylline + Theophylline	Etophylline & Theophylline Injection	169.4mg + 50.6mg per 2ml	Each 2 ml contains: Etophylline BP 169.4 mg Theophylline USP 50.6 mg	2 ml Ampoule	2 ml Ampoule	Injection	Injection	13.09.2016	08.01.2029	Generic	Submitted (page no. 64)

Amr
12/17/24Nity Bala
12/07/202416/07/24
18/7/24

6	27	Magnesium Sulphate	Magnesium Sulphate Injection IP	50% w/v	Each ml contains: Magnesium Sulphate Heptahydrate IP 500 mg	10 ml Vial	10 ml Vial	Injection	Injection	15.04.2021	08.01.2029	Generic	Submitted (page no. 78)
7	29	Meropenem	Meropenem Injection IP 500 mg	500mg	Each vial contains: Sterile Meropenem Trihydrate IP Eq. to anhydrous Meropenem IP 500 mg (Sterile sodium carbonate (as buffer) Eq. to sodium 45.1 mg)	Vial	Vial	Powder for Injection	Powder for Injection	08.12.2011	08.01.2029	Generic	Submitted (page no. 69)
8	30	Meropenem	Meropenem Injection IP 1000 mg	1g	Each vial contains: Sterile Meropenem Trihydrate IP Eq. to anhydrous Meropenem IP 1000 (sterile sodium carbonate (as buffer) Eq. to Sodium 90.2 mg)	Vial	Vial	Powder for Injection	Powder for Injection	08.12.2011	08.01.2029	Generic	Submitted (page no. 64)
9	32	Midazolam	Midazolam Injection IP	1mg/ml	Each ml contains: Midazolam IP 1 mg Benzyl Alcohol IP 1.5% v/v	5ml Vial	1 ml, 2 ml, amp. 5 ml, 10 ml, vial	Injection	Injection	25.07.2015	08.01.2029	Generic	Submitted (page no. 77)
10	34	Ondansetron	Ondansetron Injection IP	2mg/ml	Each ml contains: Ondansetron Hydrochloride Eq. to Ondansetron IP 2 mg	2 ml Ampoule	1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 10 ml, 20 ml, 30 ml	Injection	Injection	Jan-09	08.01.2029	Generic	Submitted (page no. 74)
11	36	Paracetamol	Paracetamol Injection	150mg/ml	Each ml contains: Paracetamol IP 150 mg Benzyl Alcohol IP 1.5% v/v (As preservative)	2ml Ampoule	1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 10 ml, 20 ml, 30 ml	Injection	Injection	16.07.2012	08.01.2029	Generic	Submitted (page no. 66)

Antz
R17/24

ality Balg
12/07/2024

16/7/24

TENDER NO. BMSIC/DRUGS/24-03

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Pushkar Pharma. Total Number of Pages Submitted in bid documents:- 100

Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	3	Amikacin	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
2	10	Cefotaxime	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
3	11	Ceftriaxone	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
4	12	Ceftriaxone	25 & 28	S-MNB/08/28 & S-MB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
5	19	Etophylline + Theophylline	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
6	27	Magnesium Sulphate	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
7	29	Meropenem	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024

Drisht
12/7/24Ality Bala
12/07/2024

12/07/24

H. Chandra
12/7/24

8	30	Meropenem	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
9	32	Midazolam	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
10	34	Ondansetron	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
11	36	Paracetamol	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
12	37	Promethazine	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
13	38	Sodium chloride (Normal Saline)	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
14	42	Thiamine Injection	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
15	44	Tranexamic acid	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024
16	48	Vitamin K1 (Phytomenadione or Phyloquinone)	25 & 28	MNB/08/28 & S-MNB/08/29	NA	NA	09.01.2009	08.01.2029	11.01.2023	04.12.2024

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/214-2024/3159 dt 10.07.2024 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due diligence and care. Inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discrepancies are observed for rectification.

Anta
12/7/24

Nity Bala
12/07/2024

16/7/24